Picture Health
Picture Health is a Cleveland-based AI imaging company that develops AI-powered biomarkers (QVT Score, CheckpointPx) from routine CT scans to support precision oncology trials and clinical decision-making for biopharma sponsors and clinicians.
- Company typePrivate
- Founded2026
- HeadquartersCleveland, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Picture Health firmographics
Firmographics- Name
- Picture Health
- Legal name
- Picture Health
- Website
- https://picturehealth.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Picture Health is a Cleveland-based AI imaging company that develops AI-powered biomarkers (QVT Score, CheckpointPx) from routine CT scans to support precision oncology trials and clinical decision-making for biopharma sponsors and clinicians.
- Ownership category
- akta.pro rank
Picture Health industry classification
Industry- Product category
- Precision Oncology AI Imaging Biomarkers
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Picture Health is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Markets served
Picture Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Biomarker Licensing and Development Services: Picture Health partners with biopharma companies to provide AI imaging biomarker analysis services for clinical trials. Revenue appears to come from licensing their biomarkers and custom development services for specific therapeutic mechanisms and trial goals. The company enables optimized patient stratification, early OS signal detection, and longitudinal monitoring of treatment effect for pharmaceutical clients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Picture Health product offering
Product offeringCore offering
Picture Health develops AI-powered imaging biomarkers that quantify biological properties of tumors from routine radiology and pathology scans. Its Px Platform supports both standard biomarker products (QVT Score, CheckpointPx) and custom biomarker development services for biopharma clients running oncology clinical trials. The offering enables patient stratification, early overall-survival signal detection, and longitudinal treatment-effect monitoring without requiring additional tissue or lab tests.
Product overview
Picture Health offers a platform-based portfolio centered on its Px Platform, which enables the development of custom biomarkers aligned with therapeutic mechanisms. The platform is complemented by two standard biomarker products: QVT Score (a radiomic biomarker of tumor vascularity for predicting immunotherapy and anti-angiogenic therapy response) and CheckpointPx (a multimodal AI biomarker that expands beyond PD-L1 to predict ICI outcomes). These products work together to provide interpretable, AI-driven imaging biomarkers for precision oncology throughout a patient's cancer journey.
Differentiator
Problem solved
Functional benefit
Brands
- Px Platform: AI-powered platform that transforms radiology and pathology images into actionable insights by quantifying novel biological properties of tumors and their surroundings
- QVT Score
- CheckpointPx
Products and services
- Px Platform Px Platform is Picture Health's proprietary AI platform that leverages a Feature Library to quantify tumor properties and build custom biomarkers from routine radiology and pathology images, integrating radiology, pathology, genomic, and clinical data for comprehensive tumor characterization. It is sold to biopharma companies to enable patient stratification, early overall-survival signal detection, and longitudinal treatment-effect monitoring in oncology clinical trials.
- QVT Score QVT Score (Quantitative Vessel Tortuosity) is the first and only AI biomarker that quantifies tumor vascularity and angiogenesis from routine CT imaging scans. It monitors on-treatment changes in tumor vascularity, predicts utility for anti-angiogenic therapies, and is validated across multiple checkpoint inhibitor and VEGF regimens, built on routine imaging and independent of RECIST and tumor volume.
- CheckpointPx CheckpointPx is a multimodal AI biomarker that integrates radiology, pathology, and clinical data to predict outcomes to immune checkpoint inhibitor (ICI) regimens for patients with advanced NSCLC. It is described as outperforming PD-L1 and RECIST measurements in this indication.
Quantifiable outcome
- Validated predictive associations with patient survival following immunotherapy in retrospective study of 682 patients
- +2 more outcomes
Companies that use Picture Health
Customer profileSegments2 records
Ideal customer profiles2 records
Picture Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Picture Health partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
Picture Health competitors and assessment
Company assessmentDirect peers
- Artera: Artera (formerly ArteraAI) develops AI-derived multimodal biomarkers from pathology and clinical data to predict therapy response in prostate cancer, sold to biopharma for trial stratification — the closest direct peer in AI imaging biomarkers for oncology treatment selection.
- Owkin: Owkin applies AI to multimodal patient data (imaging, pathology, omics) for biopharma drug development and trial optimization, sharing Picture Health's biopharma customer motion and imaging/AI biomarker orientation.
- PathAI: PathAI builds AI-powered pathology diagnostics and partners with biopharma on biomarker-driven trial work, with an overlapping pathology + AI + biopharma commercial model.
- Median Technologies: Median Technologies provides imaging biomarkers and AI-based image management for oncology clinical trials, directly competing in AI imaging endpoints and patient stratification services.
- Lunit: Lunit develops AI for medical imaging analysis with a growing focus on oncology biomarkers and biopharma partnerships, particularly in pathology and radiology-based response prediction.
- Paige: Paige builds AI applications for digital pathology with FDA-cleared products and biopharma biomarker collaborations, addressing a closely adjacent AI pathology/oncology biomarker niche.
Broad incumbents
- Tempus: Tempus is a broader precision medicine platform combining genomic, imaging, and clinical data with biopharma data licensing — a larger incumbent with overlapping AI biomarker capabilities and a similar biopharma GTM.
- ConcertAI: ConcertAI is an oncology real-world data and AI company that sells AI-derived insights to biopharma, overlapping with Picture Health on AI-enabled oncology evidence for drug development.
- DeepHealth (RadNet): DeepHealth, a RadNet subsidiary, applies AI to radiology imaging including oncology workflows, representing a larger incumbent in AI-powered medical imaging for clinical and trial use.
Emerging players
- Aignostics: Aignostics builds AI for pathology image analysis with biopharma partnerships for biomarker discovery, representing a comparable emerging player in AI-driven pathology biomarkers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Picture Health social profiles
Digital presencePicture Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Picture Health leadership team
Management profileNumber of profiles
Profiles10 records
Picture Health funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Picture Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Picture Health
What does Picture Health do?
Picture Health develops AI-powered imaging biomarkers that quantify biological properties of tumors from routine radiology and pathology scans. Its Px Platform supports both standard biomarker products (QVT Score, CheckpointPx) and custom biomarker development services for biopharma clients running oncology clinical trials. The offering enables patient stratification, early overall-survival signal detection, and longitudinal treatment-effect monitoring without requiring additional tissue or lab tests.
Is Picture Health a public or private company?
Picture Health is a private company. It is classified as unknown and is currently operating.
When was Picture Health founded?
Picture Health was founded in 2026. It employs 11 to 50 people.
Where is Picture Health based?
Picture Health is headquartered in Cleveland, United States, in the North America region.
How does Picture Health make money?
One revenue line is on record: biomarker Licensing and Development Services.
Who are Picture Health's main competitors?
Direct peers on record are Artera, Owkin, PathAI, Median Technologies, Lunit and Paige. Broad incumbents are Tempus, ConcertAI and DeepHealth (RadNet). Aignostics is listed as an emerging player.
Does Picture Health have an API?
No public API is recorded for Picture Health.
What industry is Picture Health in?
Picture Health's product category is Precision Oncology AI Imaging Biomarkers. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 325413 and its SIC code is 2835.